Drug news
Eviplera triple therapy ( Gilead Sciences) is EU approved for HIV-1 infection
The EMA has granted marketing authorisation for the combination drug Eviplera, from Gilead Sciences, for HIV-1 infection.Eviplera is a once-daily single-tablet that combines Truvada (tenofovir/emtricitabine) from Gilead Sciences and Edurant(rilpivirine) from Tibotec, a Johnson & Johnson company.The combination has been approved by the FDA as Complera.